Tiziana Life Sciences Ltd.: Tiziana Life Sciences Completes Enrollment of the First Patient Cohort for its Intermediate-Size Patient Population Expanded Access Program to Evaluate Foralumab in Non-Active Secondary Multiple Sclerosis Patients

NEW YORK, Nov. 02, 2022 (GLOBE NEWSWIRE) -- Tiziana Life Sciences Ltd. (Nasdaq: TLSA) ("Tiziana" or the "Company"), a biotechnology company developing breakthrough immunomodulation therapies via novel

Related Keywords

Boston ,Massachusetts ,United States ,Irina Koffler ,Hana Malik ,Gabriele Cerrone ,Tiziana Life Sciences ,Lifesci Advisors ,Tiziana Life Sciences Ltd ,Patient Population Expanded Access Program ,Nasdaq ,Business Development ,Life Sciences ,Secondary Progressive Multiple Sclerosis ,Executive Chairman ,Chief Executive Officer ,Investor Relations ,Sci Advisors ,Tiziana ,Life ,Ciences ,Ompletes ,Enrollment ,First ,Patient ,Cohort ,Intermediate ,Size ,Population ,Xpanded ,Access ,Program ,Valuate ,Foralumab ,Ctive ,Secondary ,Multiple ,Clerosis ,Patients ,